EGFR/ALK野生型晚期NSCLC患者血清miR-499 miR-144-3p变化及对预后的预测价值

doi:10.3969/j.issn.1006-6233.2023.11.011

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1304 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 分析表皮生长因子受体(EGFR)/间变性淋巴瘤激酶(ALK)野生型晚期非小细胞肺癌(NSCLC)患者血清微小RNA(miR)-499、miR-144-3p变化,并评估其对预后的预测价值。方法: 收集2018年1月至2020年我院收治的107例EGFR/ALK野生型晚期NSCLC患者临床资料(NSCLC组),另取同期健康体检者107例作为对照组,采用实时荧光RCR技术检测血清miR-499、miR-144-3p表达,比较其在两组中的差异,并评估不同临床病理特征晚期NSCLC患者血清miR-499、miR-144-3p表达的变化;以出院时为随访起点,2023年1月为截止时间,死亡为终点事件,以大于等于平均值作为高表达的标准,分别比较miR-499、miR-144-3p高表达与低表达的晚期NSCLC患者预后生存率。结果: NSCLC组血清miR-499[(0.74±0.18)vs(1.05±0.20)]、miR-144-3p相对表达量[(0.82±0.19)vs(1.22±0.21)]均低于对照组(P<0.05)。晚期NSCLC患者中,Ⅳ期患者血清miR-499[(0.64±0.17)vs(0.86±0.21)]、miR-144-3p相对表达量[(0.71±0.16)vs(0.95±0.22)]低于ⅢB及ⅢC期者(P<0.05),低分化者则低于中高分化者[(0.63±0.16)vs(0.85±0.21),(0.70±0.15)vs(0.94±0.22),P<0.05]。晚期NSCLC患者随访时间为4~56个月,中位随访时间34个月,血清miR-499高表达者生存率明显高于低表达者(P<0.05),血清miR-144-3p高表达者生存率明显高于低表达者(P<0.05)。结论: miR-499、miR-144-3p在EGFR/ALK野生型晚期NSCLC患者血清中呈低表达,Ⅳ期及低分化者表达更低,且表达水平对预后生存率有一定预测价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：非小细胞肺癌, 晚期, EGFR/ALK野生型, miR-499, miR-144-3p, 预后

Abstract：Objective: To analyze the variations in serum microRNA (miR-499) and miR-144-3p among patients with advanced non-small cell lung cancer (NSCLC) of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type,and evaluate their predictive value for prognosis. Methods: Clinical data were collected from 107 patients with EGFR/ALK wild-type advanced NSCLC who were admitted to the hospital between January 2018 and 2020 (NSCLC group).Additionally,107 healthy subjects who underwent physical examinations during the same period were selected as the control group.Real-time fluorescence RCR technology was employed to measure the expression of serum miR-499 and miR-144-3p.Differences between the two groups were compared,and changes in serum miR-499 and miR-144-3p expressions were assessed across patients with advanced NSCLC exhibiting various clinicopathological characteristics.Follow-up began at discharge and ended in January 2023,considering death as the endpoint event.The prognostic survival rate was compared between advanced NSCLC patients with high and low expressions of miR-499 and miR-144-3p,using an expression level greater than the average value as the criterion. Results: In the NSCLC group,relative expression levels of serum miR-499 [(0.74±0.18) vs (1.05±0.20)] and miR-144-3p [(0.82±0.19) vs (1.22±0.21)] were significantly lower compared to the control group (P<0.05).Among patients with advanced NSCLC,the relative expression levels of serum miR-499 [(0.64±0.17) vs (0.86±0.21)] and miR-144-3p [(0.71±0.16) vs (0.95±0.22)] were lower in stage IV patients compared to stage ⅢB and ⅢC patients (P<0.05).Furthermore,patients with lower differentiation exhibited lower expression levels compared to those with moderate-to-high differentiation [(0.63±0.16) vs (0.85±0.21),(0.70±0.15) vs (0.94±0.22),P<0.05].The follow-up duration for advanced NSCLC patients ranged from 4 to 56 months,with a median follow-up period of 34 months.Patients with high serum miR-499 expression had a significantly higher survival rate compared to those with low expression (P<0.05),as did patients with high serum miR-144-3p expression (P<0.05). Conclusion: Serum miR-499 and miR-144-3p exhibit low expression in patients with EGFR/ALK wild-type advanced NSCLC.Furthermore,their expression levels are even lower in stage IV patients and those with lower differentiation.Importantly,these expression levels hold predictive value for prognostic survival rates.

Key words： Non-small cell lung cancer Advanced EGFR/ALK wild-type miR-499 miR-144-3p Prognosis

基金资助:山东省医药卫生科技发展计划项目,(编号:2019WS365)

通讯作者: 徐保彬

引用本文:

谷振芳, 徐保彬, 李伟, 张春梅, 周亚青. EGFR/ALK野生型晚期NSCLC患者血清miR-499 miR-144-3p变化及对预后的预测价值[J]. 河北医学, 2023, 29(11): 1816-1820.
GU Zhenfang, XU Baobin, LI Wei, et al. Serum miR-499 and miR-144-3p Changes in EGFR/ALK Wild-Type Advanced NSCLC Patients and Their Predictive Value for Prognosis. HeBei Med, 2023, 29(11): 1816-1820.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.11.011 或 http://www.hbyxzzs.cn/CN/Y2023/V29/I11/1816

[1] 孟铎,张坤.同步放化疗与序贯放化疗对NSCLC患者临床疗效,肺功能与血液学毒性的影响[J].川北医学院学报,2023,38(4):526-529.
[2] 张伟,刘青春,张潍,等.circ_0000069靶向miR-338-3p对非小细胞肺癌A549细胞增殖,迁移和侵袭的影响[J].中南医学科学杂志,2023,51(2):197-201.
[3] 陶国华,赵枰,郁超.miR-133a水平降低为非小细胞肺癌的不良预后因子[J].中国实验诊断学,2021,25(11):1606-1610.
[4] Ma YS,Shi BW,Lu HM,et al.MicroRNA-499 serves as a sensitizer for lung cancer cells to radiotherapy by inhibition of CK2α-mediated phosphorylation of p65[J].Mol Ther Oncolytics,2021,21(3):171-182.
[5] Liu SW,Yang P,Li FN,et al.LncRNA B4GALT1-AS1 promotes non-small cell lung cancer cell growth via increasing ZEB1 level by sponging miR-144-3p[J].Transl Cancer Res,2022,11(3):538-547.
[6] Ya CHEN,Yanan WANG,Zhengyu YANG,等.帕博利珠单抗单药或联合化疗对PD-L1≥50%晚期NSCLC疗效的回顾性分析[J].中国肺癌杂志,2022,25(2):10007-10016.
[7] 陈志萍,黄丽珊,吴明秀,等.子痫前期患者血清miR-17miR-25表达的临床意义及对妊娠结局的影响[J].河北医学,2022,28(8):1344-1348.
[8] Li R,Yu Y,Jaafar SO,et al.Genetic variants miR-126,miR-146a,miR-196a2,and miR-499 in polycystic ovary syndrome[J].Br Biomed Sci,2022,79(7):10209.
[9] Liu C,Gao W,Shi Y,et al.Association between miR-146a rs2910164,miR-196a2 rs11614913,and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma:a case-control study[J].Cancer Med,2022,11(21):3949-3959.
[10] Li M,Zhang S,Wu N,et al.Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3[J].Sci Rep,2021,11(1):17295.
[11] Sun Y,Liu Z,Huang L,et al.MiR-144-3p inhibits the proliferation,migration and invasion of lung adenocargen cancer cells by targeting COL11A1[J].Chemother,2021,33(6):409-419.
[12] Fang G,Zhang C,Liu Z,et al.MiR-144-3p inhibits the proliferation and metastasis of lung cancer A549 cells via targeting HGF[J].Cardiothorac Surg,2022,17(1):117-127.